Abstract: 162 words Introduction: 241 words Discussion: 798 words Abbreviations: GR, glutaredoxin reductase; HEDS, 2-hydroxyethyl disulfide, TFA, trifluoroacetic acid; IAA, iodoacetamide; LC-MS/MS, liquid chromatography equipped with tandem mass spectrometry; prasugrel, 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno[3,2-c] In this study, enzymes in human liver cytosols were found to accelerate reduction of R-133490 leading to the formation of R-138727. To explore the possible reductive enzymes, we separated the various proteins in human liver cytosol based on size using gel filtration chromatography. Two active peaks were detected, and found to contain thioredoxin and glutaredoxin, respectively. Additionally, recombinant human glutaredoxin and thioredoxin promoted the formation of R-138727 from R-133490 with much higher activity for glutaredoxin than for thioredoxin. This is the first in vitro observation that glutaredoxin and thioredoxin in human liver are active in reducing the mixed disulfide formed between xenobiotics and glutathione.
pharmacologically active metabolites via a corresponding thiolactone metabolite (Farid et al., 2010) . Our previous in vitro studies suggested that one possible pathway for the hydrolysis of prasugrel to form the thiolactone, R-95913, during absorption (Williams et al., 2008) , was via oxidation to a chemically unstable sulfenic acid or S-oxide intermediate. This intermediate could then be converted to a disulfide-type glutathione conjugate (R-133490), and subsequently reduced to the pharmacologically active DMD#35196 could be immediately reduced to R-138727 in the presence of cytosol (Hagihara et al., 2010) .
In this study, we isolated and identified the enzymes in human liver cytosols catalyzing the in vitro glutathione mediated reduction of R-133490 to R-138727 as glutaredoxin and thioredoxin.
DMD#35196

Materials and Methods
Materials. Deacetylated (thiolactone) metabolite of prasugrel (R-95913), the active metabolite of prasugrel (R-138727) and its glutathione conjugate (R-133490), shown in Methoxyphenacyl bromide was purchased from Tokyo Chemical Industry Co., Ltd.
(Tokyo, Japan). All other chemicals and reagents were commercially available, and of guaranteed reagent grade.
DMD#35196
Metabolism of the glutathione conjugate of R-138727 in human liver microsomes and cytosols. A mixture (990 µL) containing glutathione (final 5 mM) and human liver microsomes or cytosols (final 1 mg/mL) in 50 mM potassium phosphate buffer (pH 7.4), was preincubated for 5 min at 37°C. The reaction was initiated by addition of 10 µL of the glutathione conjugate of R-138727 solution (final concentration: 1 µM). After incubation at 37°C for 1, 2, 5 and 10 min (total volume: 1 mL), 100 µL of the incubation mixture was mixed with 200 µL of acetonitrile, which was treated with 1 µmole of methoxyphenacyl bromide to derivatize R-138727 for LC-MS/MS assay.
R-135766 was used as the internal standard. The assays of R-138727 and R-133490
were performed following the methods previously reported (Hagihara et al., 2010) .
8 of each fraction obtained after gel filtration of a cytosol mixture or 50 mM potassium phosphate buffer (pH 7.4). The mixture was preincubated for 5 min at 37°C. The reaction was initiated by addition of 25 µL of R-133490 solution in distilled water (final 0.1 mM). After incubation at 37°C for 0, 5 and 10 min (total volume: 250 µL), 30 µL of the incubation mixture was transferred to a centrifuge tube, and 90 µL of acetonitrile was added to the tube. The mixture was mixed well and centrifuged at 15,000g for 3 min at 4°C. In inhibition experiments with anti-human glutaredoxin IgG, 70 µL of the gel filtrated active fraction was mixed with 10 µL of anti-human glutaredoxin IgG (final concentrations: 33 to 300 µg/mL), and preincubated for 2 hr at 37°C followed by measurement of the activity to produce R-138727 with 0.1 mM R-133490 and 5 mM glutathione as final concentrations. In inhibition experiments with anti-human thioredoxin IgG, 30 µL of the gel filtrated active fraction was mixed with 60 µL of anti-human thioredoxin IgG (final concentrations: 67 to 600 µg/mL), and preincubated for 1 hr at 37°C followed by measurement of the activity to produce R-138727 with 0.05 mM R-133490 and 5 mM glutathione as final concentrations. Mouse IgG was used as a control. Twenty five µL of supernatant was injected into an HPLC system for measurement of R-138727. The HPLC system (SHIMADZU) consisted of a system controller (LC-10AD), auto injector (SIL-10AXL), UV-VIS detector DMD#35196 (SRD-10A), column oven (CTO-10AL) and degasser (DGU-12A). A YMC-ODS A-302 column (4.6x150 mm) was used as an analytical column, and a mixture of acetonitrile, isopropyl alcohol, distilled water and trifluoroacetic acid (TFA) (5/12/83/0.01, v/v/v/v) was used as mobile phase at a flow rate of 0.5 mL/min.
Absorption at 220 nm was monitored to detect R-138727. The lower limit of quantification was 1 µM, and the intra-assay reproducibility was confirmed in the range of 1 µM to 100 µM. with 1% rabbit serum in 0.05% Tween -Tris Buffered Saline (TBS, mixture of 20 mM
Tris and 500 mM NaCl, pH 7.5) (0.05% TBS) for 30 min at room temperature, and was reacted with goat anti-human glutaredoxin IgG (2 µg/mL) in 0.05% TBS for 30 min.
After washing with Sample buffer, the membrane was incubated with biotinylated Protein identification by mass spectrometry. Five µL of the gel-filtrated active fraction of the human hepatic cytosol (active peak 2 from gel-filtration separation) was mixed with 10 µL of Laemmli sample buffer (Bio-Rad Laboratories) containing 5% 2-mercaptoethanol. After heat-denaturing the enzyme for 2 min at 95 °C, the mixture was loaded for SDS-polyacrylamide gel electrophoresis (15% gel, Bio-Rad Laboratories). The gel was stained with a Zinc stain Kit (Bio-Rad Laboratories).
The protein in an excised gel piece was digested according to the procedure described by Wilm et al. (1996) . Bands excised from the gel were destained with 2.5 mM Tris
This article has not been copyedited and formatted. The final version may differ from this version. introduced directly into the ion trap mass spectrometer (LCQ, ThermoQuest, San Jose, CA) with an electrospray ion source using an in-house-built spray mount. During a run, if an ion was present in the scan above a specified threshold, the mass spectrometer automatically alternated among full MS, zoom scan (high resolution but narrow mass range), and MS/MS modes, so that the masses and the amino acid sequence information of the peptides could be obtained.
The resulting tandem mass spectra were searched against the Swiss-Prot database respective mean values were substituted into eq 1.
The intrinsic clearance (CL int ) was calculated as a ratio of V max to K m . These parameters are expressed as mean±SD.
This article has not been copyedited and formatted. The final version may differ from this version. Two active peaks (designated as active peak 1 and 2) were detected in the presence of 5 mM glutathione. R-138727 producing activities of these two peaks were much lower (about 2.5-fold at most relative to glutathione alone) than the activity found with human liver cytosol (Figures 2a and 2b) , possibly indicating the decrease of enzymatic activities during the purification process.
Contribution of glutaredoxin to R-138727 producing activities in human liver cytosols.
Since it has been reported that glutaredoxin is highly selective for glutathione containing mixed disulfides (Srinivasan et al., 1997) , we investigated the involvement of glutaredoxin in R-138727 formation from R-133490 in human liver cytosols. By
Western blot analysis using anti human glutaredoxin antibody, active peak 2, but not active peak 1, was found to contain glutaredoxin (Figure 4 ). Glutaredoxin was also identified from peak 2 by mass spectrometry of the trypsin digests of the bands extracted from the SDS-PAGE gels ( Figure 5 ).
The activity to produce R-138727 in active peak 2, but not in active peak 1, was significantly inhibited by anti human glutaredoxin antibody in the presence of 5 mM glutathione ( Figure 6a ). R-138727 formation by active peak 1 in the presence of 300
This article has not been copyedited and formatted. The final version may differ from this version. μ g/mL of anti human glutaredoxin antibody increased without known cause. The activity in peak 2 was not entirely inhibited probably due to other enzymes present or to non-enzymatic reduction by glutathione.
Contribution of thioredoxin to R-138727 producing activities in liver cytosols.
Thioredoxin is well known as an enzyme similar to glutaredoxin in its structure and enzymatic characteristics. Therefore we thought that thioredoxin may be the enzyme responsible for the activity found in peak 1. The activity to produce R-138727 in active peak 1 was significantly inhibited by 600 
Discussion
In this study, we focused on the possible enzymes mediating R-138727 formation from R-133490. The primary purpose was to isolate and identify the reductive enzymes in human liver cytosol that could possibly mediate R-138727 formation from R-133490.
Using gel filtration chromatography, two different peaks (active peak 1 and 2) that could catalyze the reaction were found in human liver cytosol. The R-138727 producing activities in active peak 1 and 2 from a cytosol were inhibited by anti thioredoxin and anti glutaredoxin antibodies, respectively, indicating thioredoxin and glutaredoxin as the main enzymes in active peak 1 and 2, respectively.
Contribution ratios of active peak 1 and active peak 2 (expected as thioredoxin and glutaredoxin, respectively) could be estimated based on the peak areas under the FPLC fraction number -R-138727 producing activity curve (AUC) after subtracting the concentrations of R-138727 formed with 5 mM glutathione alone in potassium phosphate buffer (dotted line in Figure 3 ). The R-138727 producing AUC of active peak 2 were approximately 3 times higher than that of active peak 1, indicating that glutaredoxin contributes to a greater extent to the formation of R-138727 in human liver than thioredoxin. Moreover, we compared intrinsic clearance values on the formation This article has not been copyedited and formatted. The final version may differ from this version. in reducing glutathione-protein mixed disulfide (Jung et al., 1996) . In spite of such efficient ability of recombinant glutaredoxin to reduce R-133490, active peak 2 isolated from human liver cytosol showed only three-fold higher activity than active peak 1, possibly indicating that less glutaredoxin is present in human liver cytosols than thioredoxin. In this study, glutaredoxin showed higher substrate specificity than Human cells contain three glutaredoxins: the cytosolic Grx1 with the active site
Cys-Pro-Tyr-Cys; the primary mitochondrial Grx2 containing the active site
Cys-Ser-Tyr-Cys; anothoer mitochondrial Grx5 with only one Cys residue (Cys-Gly-Phe-Ser) in its active site (Berndt et al., 2007) . For thioredoxin, human genome encodes one cytosolic Trx1 and one mitochondrial Trx2 (Meyer et al., 2009) .
Given this information, the thioredoxin and glutaredoxin in active peaks 1 and 2, respectively, are considered likely to be Trx1 and Grx1, respectively. As reduction of R-133490 was also promoted by human liver microsomes (Figure 2c ), Grx2 or Grx5
and Trx2 may also be contributing to the activity.
Glutaredoxin has been purified and identified from rat liver (Maellaro et al., 1994) , human blood (Papov VV et al., 1994) , human brain (Fernando MR et al., 1994) , human placenta (Padilla CA et al., 1995) , human lung (Peltoniemi M et al., 2004) and human lens (Qiao F et al., 2001 ). In addition, thioltransferase activities in human hepatic cell DMD#35196 lines have been reported (Yuk-Young Lee, 2002) . However, identification of glutaredoxin from human liver has not been reported. Also, thioredoxin has been identified from human lens (Reddy PG et al., 2000) , brain (Xu JY et al., 2000) and cervix (Strausberg RL et al., 2002) , but not from liver. Therefore, the present study is the first report showing that glutaredoxin and thioredoxin are present in human liver cytosol. Moreover, human glutaredoxin and thioredoxin have not been reported to reduce the mixed disulfide of xenobiotics with glutathione even though these enzymes isolated from E. coli are reported to be active on the reduction of S-S dimer xenobiotics (Verschraagen et al., 2004) . Accordingly, this study is also the first report showing that glutaredoxin and thioredoxin in human liver functionally reduce the mixed disulfide of xenobiotics with glutathione.
In conclusion, glutaredoxin and thioredoxin in human liver cytosols could work as reductive enzymes in the formation of the pharmacologically active metabolite of prasugrel from its glutathione conjugate with much higher activity for glutaredoxin.
This article has not been copyedited and formatted. The final version may differ from this version. Ten microlitters of the active peak 2 was subjected to SDS-PAGE in reducing condition.
To confirm the presence of human glutaredoxin, the 7 bands close to the glutaredoxin This article has not been copyedited and formatted. The final version may differ from this version. After incubation at 37 °C for 5 min, the reaction was stopped by mixing with three times volume of acetonitrile. The data are expressed as the mean+SD (n=3).
Background level of R-138727 production determined in the presence of glutathione alone was described as dotted line. * P < 0.05, ** P < 0.01 vs 0 concentration,
Dunnett test.
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